Clinical Trial Update: PD-1 Inhibitor Tislelizumab Maintenance Therapy in R/R DLBCL Patients After ASCT [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating maintenance therapy with the PD-1 inhibitor tislelizumab in relapsed/refractory diffuse large B-cell lymphoma after autologous stem cel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Ruijin Hospital | Conditions: Lymphoma, Large B-Cell, Diffuse, Transplantation | Phase 3 | Status: UNKNOWN